Choon Ta NG

Dr. Choon Ta NG

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in JACC
Verified
Journal Article
Open access
AMAdriana Marton
Adriana Marton
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
MRManfred Rauh
Manfred Rauh
RSRuo-Ning Sun
Ruo-Ning Sun
ANArmin M. Nagel
Armin M. Nagel
JTJens Titze
Jens Titze
Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential. The goal of this study was to test the hypothesis that vasopressin-driven urine concentration overrides the osmotic diuretic effect of glucosuria induced by dapagliflozin treatment. DAPA-Shuttle1 (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment) was a single-center, double-blind, randomized, placebo-controlled trial, in which patients with chronic heart failure NYHA functional classes I/II and reduced ejection fraction were randomly assigned to receive dapagliflozin 10 mg daily or placebo (1:1) for 4 weeks. The primary endpoint was change from baseline in urine osmolyte concentration. Secondary endpoints included changes in copeptin levels and solute free water clearance. Thirty-three randomized, sodium-glucose cotransporter 2 inhibitor-naïve participants completed the study, 29 of whom (placebo: n = 14; dapagliflozin: n = 15) provided accurate 24-hour urine collections (mean age 59 ± 14 years; left ventricular ejection fraction 31% ± 9%). Dapagliflozin treatment led to an isolated increase in urine glucose excretion by 3.3 mmol/kg/d (95% CI: 2.51-4.04; P < 0.0001) within 48 hours (early) which persisted after 4 weeks (late; 2.7 mmol/kg/d [95% CI: 1.98-3.51]; P < 0.0001). Dapagliflozin treatment increased serum copeptin early (5.5 pmol/L [95% CI: 0.45-10.5]; P < 0.05) and late (7.8 pmol/L [95% CI: 2.77-12.81]; P < 0.01), leading to proportional reductions in free water clearance (early: -9.1 mL/kg/d [95% CI: -14 to -4.12; P < 0.001]; late: -11.0 mL/kg/d [95% CI: -15.94 to -6.07; P < 0.0001]) and elevated urine concentrations (late: 134 mmol/L [95% CI: 39.28-229.12]; P < 0.01). Therefore, urine volume did not significantly increase with dapagliflozin (mean difference early: 2.8 mL/kg/d [95% CI: -1.97 to 7.48; P = 0.25]; mean difference late: 0.9 mL/kg/d [95% CI: -3.83 to 5.62]; P = 0.70). Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment [DAPA-Shuttle1]; NCT04080518).

25 July 2023 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
CNChoon Ta NG
Choon Ta NG
HBHilda M. Gonzalez Bonilla
Hilda M. Gonzalez Bonilla
ABAlan H. Bryce
Alan H. Bryce
PSParminder Singh
Parminder Singh
JHJoerg Herrmann
Joerg Herrmann

1 January 2023 in Korean Circulation Journal
Verified
Journal Article
Open access
CNChoon Ta NG
Choon Ta NG
LTLi Ling Tan
Li Ling Tan
ISIl Suk Sohn
Il Suk Sohn
HBHilda Gonzalez Bonilla
Hilda Gonzalez Bonilla
TOToru Oka
Toru Oka
JHJoerg Herrmann
Joerg Herrmann
Korean Circulation Journal 대한심장학회지 순환기 Ng CT, et al. Korean Circ J. 2022 Nov;52:e109. https://doi.org/10.4070/kcj.2022.0255

21 April 2023 in JACC: Case Reports
Verified
Journal Article
Open access
CNChoon Ta NG
Choon Ta NG
HBHilda M. Gonzalez Bonilla
Hilda M. Gonzalez Bonilla
ICIan Chang
Ian Chang
MAM. Tun Aung
M. Tun Aung
JGJennifer J. Gile
Jennifer J. Gile
JHJoerg Herrmann
Joerg Herrmann
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life-threatening complications such as ventricular rupture, cardiac tamponade, and circulatory failure. We present a case series of patients with lymphoma and cardiomyopathy or cardiac metastasis managed with chimeric antigen receptor T-cell therapy. (Level of Difficulty: Advanced.)

26 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MJMi-Hyang Jung
Mi-Hyang Jung
MJMoon-kyung Jung
Moon-kyung Jung
EKEui-Soon Kim
Eui-Soon Kim
JYJong-Chan Youn
Jong-Chan Youn
ELEun Young Lee
Eun Young Lee
HKHyeon Chang Kim
Hyeon Chang Kim
Background/Objectives: Cancer survivors increasingly face cardiovascular disease (CVD), with diabetes as a major risk factor. This study investigates the relationship between adherence to antidiabetic medications and cardiovascular (CV) outcomes in cancer patients. Methods: Using data from the Korean National Health Insurance Service—National Sample Cohort, we assessed the clinical outcomes of adult cancer patients prescribed antidiabetic medications. The study population was categorized based on medication adherence, as determined by the medication possession ratio (MPR): good (MPR ≥ 0.8), moderate (0.5 ≤ MPR < 0.8), and poor (MPR < 0.5) adherence. The primary outcomes included overall and CV mortality, with secondary outcomes encompassing hospitalization for major CVDs and healthcare costs. Results: Among the 7928 cancer patients with diabetes, 59.7% were nonadherent (22.1% with moderate and 37.6% with poor adherence). Over a median follow-up of 5.7 years, 1462 deaths and 2897 CV events were confirmed. Multivariable adjusted analyses showed a 1.70-fold and 2.11-fold higher risk of overall mortality for the moderate and poor adherence groups, respectively, compared to the good adherence group. For CV mortality, moderate adherence was associated with a 1.51-fold higher risk, and poor adherence with a 2.10-fold higher risk. The risk for new-onset CV events increased by 1.32-fold in the moderate adherence group and 1.44-fold in the poor adherence group. The good adherence group also showed significantly lower total healthcare costs compared to the nonadherence group. Conclusions: The present study underscores the importance of adherence to antidiabetic medications in cancer patients, revealing significant associations with decreased mortality, CV events, and healthcare costs.

10 September 2021 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HPHawani Sasmaya Prameswari
Hawani Sasmaya Prameswari
IBIswaree Devi Balakrishnan
Iswaree Devi Balakrishnan
CKChun Yuan Khoo
Chun Yuan Khoo
LTLoon Yee Teo
Loon Yee Teo
LCLihua Laura Chan
Lihua Laura Chan
CNChoon Ta NG
Choon Ta NG
Background: Acute perimyocarditis is a rare extra-intestinal manifestation in Crohn’s disease which required multimodality imaging to confirm the diagnosis. Here we present a case of acute perimyocarditis as the first presentation of Crohn’s disease. To date, this is the first case presentation reporting the use of 18F-FDG PET/CT Scan for diagnosing such condition. Case presentation: A 25-year-old male presented to our hospital with severe persistent pleuritic sharp left-sided chest pain. This was his second hospital admission in the past 4 months for chest pain and diarrhea. At the first hospitalization, he was diagnosed with viral perimyocarditis and irritable bowel syndrome. Laboratory findings, electrocardiogram, and cardiac magnetic resonance imaging results confirm the diagnostic of perimyocarditis. Virology, bacteriology, parasitology, and autoimmune evaluations were unremarkable. Colonoscopy, colorectal biopsy, and 18FGD PET findings confirmed manifestation of perimyocarditis, Crohn’s disease, and negative for sarcoidosis. Conclusions: Looking at the overall clinical picture and investigation results of colonoscopy, colorectal biopsy findings, as well as multi-modality imaging with echocardiography, 18FDG PET—scan and CMRI, the patient was diagnosed to have perimyocarditis attending Chron’s disease flare up as a rare extra-intestinal manifestation.